Production of a drug for kidney treatment has begun at the Moscow SEZ “Technopolis.”

"Production of Kidney Disease Drug Launched at the Technopolis Moscow SEZ

The resident company R-Opra has launched production of a new drug for the treatment of severe forms of chronic kidney disease at the Alabushevo site of the Technopolis Moscow SEZ. The news was announced by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

“Technopolis Moscow SEZ is one of the country’s leading centers for pharmaceutical development. Under the instruction of Sergey Sobyanin, the city provides comprehensive support to companies engaged in developing and manufacturing modern medicines. One SEZ resident has registered and launched production of a drug based on a synthetic analogue of vitamin D for the treatment of severe chronic kidney failure. The company has invested a total of 8.7 billion rubles in expanding its production facilities within the capital’s SEZ,” said Maxim Liksutov.

The active ingredient of the drug is paricalcitol. Production is carried out at the R-Opra plant, which is part of the R-Pharm Group.

“The new drug is manufactured in soft gelatin capsule form and involves a full production cycle — from synthesizing the active pharmaceutical substance, conducting clinical trials, and quality control to obtaining the finished dosage form. The company has been a resident of the Technopolis Moscow SEZ since 2019 and has created over 280 high-tech jobs in that time,” noted Anatoly Garbuzov, Moscow Government Minister and Head of the Department of Investment and Industrial Policy.

As emphasized by Gennady Degtev, CEO of the Technopolis Moscow SEZ, the company is actively expanding within the capital’s special economic zone. Last year, for example, it opened a research center at the Pechatniki site, where innovative drugs are being developed to treat cancer, infectious, and other socially significant diseases.

The R-Pharm Group has signed three offset contracts with the city, under which Moscow is already receiving drugs for oncology, cardiology, and other treatments. Starting in 2026, deliveries will include immunosuppressants as well as medicines for diabetes, cardiovascular, neurological, and rheumatological diseases, and ulcerative colitis.

“The company is steadily expanding its product portfolio, bringing new and effective medicines to market. This has been made possible by R-Pharm’s powerful production base, including its facilities in the Moscow SEZ. Today, the full pharmaceutical production cycle — from substance synthesis to finished dosage form — is ensured, which is crucial for strengthening the country’s pharmaceutical security. Chronic kidney disease, according to experts, may become the fifth leading cause of reduced life expectancy in the coming years. That is why it is especially important to ensure patients have stable access to modern therapies,” said Vasily Ignatiev, CEO of R-Pharm Group."